Affimed (AFMD) to Release Earnings on Thursday

Affimed (NASDAQ:AFMD) will issue its quarterly earnings data before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($1.14) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Affimed (NASDAQ:AFMD) last released its earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.09). The business had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $1.67 million. Affimed had a negative return on equity of 155.30% and a negative net margin of 2,922.74%. On average, analysts expect Affimed to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Affimed Stock Performance

Shares of AFMD opened at $3.76 on Wednesday. Affimed has a 12-month low of $2.92 and a 12-month high of $8.95. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.71 and a quick ratio of 2.71. The business’s 50 day moving average is $3.50 and its 200 day moving average is $4.55.

Analyst Upgrades and Downgrades

AFMD has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Affimed in a report on Friday, September 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a research note on Monday, September 9th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Affimed currently has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.